CN106726009A - Sustainer intervenes valve manufacture method - Google Patents
Sustainer intervenes valve manufacture method Download PDFInfo
- Publication number
- CN106726009A CN106726009A CN201710127726.5A CN201710127726A CN106726009A CN 106726009 A CN106726009 A CN 106726009A CN 201710127726 A CN201710127726 A CN 201710127726A CN 106726009 A CN106726009 A CN 106726009A
- Authority
- CN
- China
- Prior art keywords
- valve
- cell
- sustainer
- manufacture method
- vics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2415—Manufacturing methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Manufacturing & Machinery (AREA)
- General Chemical & Material Sciences (AREA)
- Prostheses (AREA)
Abstract
The present invention relates to arterial intervention valve in implantable vessel, sustainer intervention valve manufacture method is disclosed, step 1, directional induction in vitro iPSCs are divided into valve VICs, VECs precursor.Step 2, from porcine aortic valve, original valve cell is removed using enzyme+detergent.Step 3, core shell structure fiber state controlled drug delivery system is set up with protein powder process.The controllable skin-core structure superfine composite yarn of step 4, structure degradation behavior.Step 5, by plasma etching process modification remove cell valve matrix microscopic pattern.Step 6, the controlled release by 3D printing cellular localization and drug concentration gradient.Establishment and method for shaping using Nitinol wire material, produce nick-eltitanium alloy stent.Realize outside the automatic control extensional energy of support, and reach human aortic valve and most preferably accept state.Original aortic valve attachment valve cell is removed using the method for enzyme+detergent, while completely remaining cellular matrix, the durability and anticalcium performance of product is improve.
Description
Technical field
The present invention relates to arterial intervention valve in implantable vessel, especially sustainer intervention valve manufacture method.
Background technology
Aortic stenosis is a kind of common senile degenerative cardiac valve disease, with the increase incidence of disease at age
Gradually rise, the incidence of disease of AS is up to 4.6% in more than 75 years old elderly population.It is to grind in recent years through conduit aorta petal implantation
A kind of brand-new minimally invasive valve replacement technology of hair, as it is gradually applied to clinic, is likely to become the main for the treatment of severe AS
One of method.In the prior art, sustainer intervention valve can not better adapt to aortic flow, and there is endurance quality and resist
The defect of calcification poor performance.
The content of the invention
For the defect in the presence of above-mentioned background technology, technical scheme is as follows：
On the one hand provide a kind of sustainer and intervene valve manufacture method, comprise the following steps：
Step 1, directional induction in vitro iPSCs are divided into valve VICs, VECs precursor；
Step 2, from porcine aortic valve, original valve cell is removed using enzyme and detergent, retain ECM, acquisition is gone thin
Born of the same parents' valve matrix；
Step 3, core shell structure fiber state controlled drug delivery system is set up with protein powder process；
Step 4, the controllable skin-core structure superfine composite yarn of degradation behavior is built using embedded composite spinning method；
Step 5, by plasma etching process modification remove cell valve matrix microscopic pattern, in institutional framework and weaving mode
In, superfine composite yarn is combined closely with cell valve matrix is gone, on the premise of host material institutional framework is not influenceed,
Cell valve host material biomechanical property is removed in improvement, and realizes signaling molecule gradient controlled-release, local environment is simulated physiology；
Step 6, the controlled release by 3D printing cellular localization and drug concentration gradient, inducing cell adhesion, migration and propagation,
Reconstruction structure and the cell component sustainer intervention valve similar to natural valve.
Preferably, the signaling molecule in the step 5 is growth factor TGF, FGF.
In a preferred embodiment, the step 6 includes：
Step 61, VICs precursors are mixed in collagen hydrogels, are then beaten using multidirectional branch, low-loss 3D
Impression method, positioning is planted in the enhanced host material both sides of yarn；
Step 62, in yam surface chitin fiber degradation process, for cell growth provides three dimensions；
Step 63, VECs precursors are positioned by 3D printing it is planted in host surface, stress field stimulates and promotes
Cell adhesion, is then that two kinds of cells are well merged with cell valve groundmass composite material is removed, reconstruction sustainer intervention valve.
In a preferred embodiment, the three dimensions of the step 62 is：Controlled release FGF, TGF bioactive molecule concentration
Difference and mechanism poor rigidity, induction VICs precursors are migrated by top layer inner layer, then form the cellular matrix material of rivet arrangement
Expect the system that organically blends.
A technical scheme in above-mentioned technical proposal has the advantages that：
, closer to the tricuspid valve structure of human body, the valve closure of growth naturally is compared with manual suture for the structure of porcine aorta valve
It is tighter, aortic flow effect can be better conformed to after implantation human body.Original active is removed using the method for enzyme+detergent
Arteries and veins valve adheres to valve cell, while cellular matrix is completely remained, it is real on the basis of animal source material immunological rejection is solved
Show the physiological function of simulation human aortic valve, improve the durability and anticalcium performance of product, and in production process
Life organized enzyme used is not polluted to environment.
Brief description of the drawings
In order to illustrate more clearly about the embodiment of the present invention or technical scheme of the prior art, below will be to embodiment or existing
The accompanying drawing to be used needed for having technology description is briefly described, it should be apparent that, drawings in the following description are only this
Some embodiments of invention, for those of ordinary skill in the art, on the premise of not paying creative work, can be with
Other accompanying drawings are obtained according to these accompanying drawings.
Fig. 1 is in one embodiment of the present invention, directional induction in vitro iPSCs breaks up in sustainer intervention valve manufacture method
It is valve VICs, VECs precursor flow chart；
Fig. 2 be one embodiment of the present invention in, a kind of structural representation of implementation method of nick-eltitanium alloy stent；
Fig. 3 be one embodiment of the present invention in, the structural representation of nick-eltitanium alloy stent another embodiment；
Fig. 4 be one embodiment of the present invention in, the structural representation of nick-eltitanium alloy stent another embodiment；
Fig. 5 be one embodiment of the present invention in, the structural representation of nick-eltitanium alloy stent another embodiment；
Fig. 6 be one embodiment of the present invention in, the structural representation of nick-eltitanium alloy stent another embodiment.
Specific embodiment
Below in conjunction with accompanying drawing of the invention, technical scheme is clearly and completely described, it is clear that institute
The embodiment of description is only a part of embodiment of the invention, rather than whole embodiments.Based on the embodiment in the present invention,
The every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, belongs to this hair
The scope of bright protection.
As shown in Figure 1 and Figure 2, a kind of one embodiment of the present of invention, sustainer intervenes valve manufacture method, including following step
Suddenly：
Step 1, directional induction in vitro iPSCs are divided into valve VICs, VECs precursor.
Using different cytokines and micromolecular compound and matrix dimension, stiffness combine, (inductivity is more for induction iPSCs
Function stem cell) vitro differentiation be VICs, VECs precursor.
Step 2, from porcine aortic valve, original valve cell is removed using enzyme and detergent, retain ECM, acquisition is gone thin
Born of the same parents' valve matrix.
, closer to the tricuspid valve structure of human body, the valve closure of growth naturally is compared with manual suture for the structure of porcine aorta valve
It is tighter, aortic flow effect can be better conformed to after implantation human body.Preferably, vessel segment of the collection with flap is easy to valve
The fixation of film and with support suture.
Valve bracket uses nick-eltitanium alloy stent, Nitinol wire material weaving to develop adaptation human aortic
The metallic support of structure, the temperature memory characteristic of Nitinol wire material solves asking for automatic expansion after product release well
Topic.
Establishment and method for shaping using Nitinol wire material, produce nick-eltitanium alloy stent.Realize the automatic control of support
Extensional can be outer, and the radial support power of support can be adjusted by the density for adjusting support grid, reaches human aortic valve most
It is good to accept state.For vascular stent material, in order to avoid the thrombosis after implantation, it is desirable to which material has promotion endothelial growth
Quick endothelialization function.But titanium and Nitinol are in itself without the Ni that there is toxicity in bioactivity, and Nitinol2+From
The effusion problem of son, prevents it to be grown into and quick endothelialization from being effectively promoted bone tissue.In titanium and nitinol alloy wire surface system
Standby bioactivity coatings, improve the surface-active of implantation human body, accelerate the growth around implant.
Original aortic valve attachment valve cell is removed using the method for enzyme+detergent, while completely remaining cell
Matrix, on the basis of animal source material immunological rejection is solved, realizes the physiological function of simulation human aortic valve, improves
The durability and anticalcium performance of product, and life organized enzyme used in production process do not pollute to environment.
Step 3, core shell structure fiber state controlled drug delivery system is set up with protein powder process.
Step 4, the controllable skin-core structure superfine composite yarn of degradation behavior is built using embedded composite spinning method.
Step 5, by plasma etching process modification remove cell valve matrix microscopic pattern, in institutional framework and weaving mode
In, superfine composite yarn is combined closely with cell valve matrix is gone, on the premise of host material institutional framework is not influenceed,
Cell valve host material biomechanical property is removed in improvement, and realizes signaling molecule gradient controlled-release, local environment is simulated physiology.Letter
Number molecule is growth factor TGF, FGF.
Step 6, the controlled release by 3D printing cellular localization and drug concentration gradient, inducing cell adhesion, migration and propagation,
Reconstruction structure and the cell component sustainer intervention valve similar to natural valve.
Step 61, VICs precursors are mixed in collagen hydrogels, are then beaten using multidirectional branch, low-loss 3D
Impression method, positioning is planted in the enhanced host material both sides of yarn.
Step 62, in yam surface chitin fiber degradation process, for cell growth provides three dimensions.
Controlled release FGF, TGF bioactive molecule concentration difference and mechanism poor rigidity, induction VICs precursors are moved by top layer inner layer
Move, the cell matrix materials for then forming rivet arrangement organically blend system.
Step 63, VECs precursors are positioned by 3D printing it is planted in host surface, stress field stimulates and promotes
Cell adhesion, is then that two kinds of cells are well merged with cell valve groundmass composite material is removed, reconstruction sustainer intervention valve.
As shown in figure 1, the reprogramming of (1) SF obtains iPSCs；
(2) induction iPSCs is divided into valve VICs, VECs precursor, iPSCs-lateral plate mesoderm cell-precursor blood
Endothelial cell-precursor endocardial cells-valve VICs and valve VECs.
During induction iPSCs is divided into valve VICs, VECs precursor, study different condition of culture (cell because
Son and micro mechanics environment) on inducing effect influence, induction iPSCs to valve like cell break up, specify directed differentiation efficiency and
Cell purity.
Nick-eltitanium alloy stent as shown in figures 2-6, support includes：Aortic stents 4, valve bracket 5 and the stream being sequentially connected
The netted tubular construction that access support 6 is constituted.The top of aortic stents 4 is fixedly connected with fixed ear 60, for being implanted into human body
When be engaged with conveying device.There are three fixed ears 60 on the top of aortic stents 4, fixed ear 60 is T-shape structure, and
The tip height of three fixed ears 60 is inconsistent.
Three void regions 7 are distributed with the side wall of valve bracket 5, void region 7a and void region 7b is used in three leaves
The top 8a of the valve and top 8b of valve is accommodated during valve-open respectively.Three-leaflet valve is shown in figure to have opened, valve
The top 8a of film and the top 8b of valve insert void region 7a and void region 7b just.
It is big that the side wall that can come in contact collision on the top with three valves in support of the present invention has held three Area comparisons
Void region, like this, three tops of valve are respectively implanted corresponding void region just when three-leaflet valve is opened, can be with
The shock to valve bracket is avoided, three-leaflet valve and support is protected.
The position contacted with heart in valve bracket be provided with positioning thorn 9a and positioning thorn 9b, positioning thorn 9a and positioning pierce 9b from
Valve bracket outer wall is downward-sloping to be stretched out and away from support axis.Be provided with altogether three positioning thorn, due in angle problem figure only
See positioning thorn 9a and positioning thorn 9b, three positioning thorns are spaced apart with three void regions 7.The length for positioning thorn is 1cm, in order to
Just with processing, the node of the unit grid of support is cut, the part that freely swings above the node is turned up and is formed positioning
Thorn.
The above, specific embodiment only of the invention, but protection scope of the present invention is not limited thereto, and it is any
Those familiar with the art the invention discloses technical scope in, change or replacement can be readily occurred in, should all contain
Cover within protection scope of the present invention.Therefore, protection scope of the present invention should be based on the protection scope of the described claims.
Claims (4)
1. sustainer intervenes valve manufacture method, it is characterised in that comprise the following steps：
Step 1, directional induction in vitro iPSCs are divided into valve VICs, VECs precursor；
Step 2, from porcine aortic valve, original valve cell is removed using enzyme+detergent, retain ECM, cell valve base is removed in acquisition
Matter；
Step 3, core shell structure fiber state controlled drug delivery system is set up with protein powder process；
Step 4, the controllable skin-core structure superfine composite yarn of degradation behavior is built using embedded composite spinning method；
Step 5, by plasma etching process modification remove cell valve matrix microscopic pattern, in institutional framework and weaving mode,
Superfine composite yarn is combined closely with cell valve matrix is gone, on the premise of host material institutional framework is not influenceed, is changed
It is kind to remove cell valve host material biomechanical property, and signaling molecule gradient controlled-release is realized, local environment is simulated physiology；
Step 6, the controlled release by 3D printing cellular localization and drug concentration gradient, inducing cell adhesion, migration and propagation, reconstruction
Structure and the cell component sustainer intervention valve similar to natural valve.
2. sustainer according to claim 1 intervenes valve manufacture method, it is characterised in that the signal point in the step 5
Son is growth factor TGF, FGF.
3. sustainer according to claim 1 intervenes valve manufacture method, it is characterised in that the step 6 includes：
Step 61, VICs precursors are mixed in collagen hydrogels, then using multidirectional branch, low-loss 3D printing side
Method, positioning is planted in the enhanced host material both sides of yarn；
Step 62, in yam surface chitin fiber degradation process, for cell growth provides three dimensions；
Step 63, VECs precursors are positioned by 3D printing it is planted in host surface, stress field stimulates and promotes cell
Stick, be then that two kinds of cells are well merged with cell valve groundmass composite material is removed, reconstruction sustainer intervention valve.
4. sustainer according to claim 3 intervenes valve manufacture method, it is characterised in that the three dimensions of the step 62
For：Controlled release FGF, TGF bioactive molecule concentration difference and mechanism poor rigidity, induction VICs precursors are migrated by top layer inner layer, after
The system and cell matrix materials for forming rivet arrangement organically blend.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710127726.5A CN106726009A (en) | 2017-03-06 | 2017-03-06 | Sustainer intervenes valve manufacture method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710127726.5A CN106726009A (en) | 2017-03-06 | 2017-03-06 | Sustainer intervenes valve manufacture method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106726009A true CN106726009A (en) | 2017-05-31 |
Family
ID=58962428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710127726.5A Pending CN106726009A (en) | 2017-03-06 | 2017-03-06 | Sustainer intervenes valve manufacture method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106726009A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331227A (en) * | 2018-09-18 | 2019-02-15 | 武汉纺织大学 | A method for improving mechanical properties of heart valve |
| CN113198045A (en) * | 2021-04-29 | 2021-08-03 | 武汉纺织大学 | Fitting type biological valve and preparation method thereof |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996032905A1 (en) * | 1995-04-19 | 1996-10-24 | St. Jude Medical, Inc. | Matrix substrate for a viable body tissue-derived prosthesis and method for making the same |
| CN1410036A (en) * | 2002-11-15 | 2003-04-16 | 谭强 | Tissue engineered valve |
| CN1775304A (en) * | 2005-11-30 | 2006-05-24 | 中国科学院上海硅酸盐研究所 | Preparation method of biologically active artificial biological valve |
| CN101385870A (en) * | 2008-11-03 | 2009-03-18 | 中国人民解放军第四军医大学 | A method for improving decellularized tissue engineering valve/vascular stent |
| CN101548916A (en) * | 2009-05-08 | 2009-10-07 | 乐普（北京）医疗器械股份有限公司 | A medical equipment carrying extracellular matrix and its production method |
| CN103263381A (en) * | 2013-05-28 | 2013-08-28 | 武汉纺织大学 | Fiber type controllable drug sustained release system and preparation method thereof |
| US8679176B2 (en) * | 2007-12-18 | 2014-03-25 | Cormatrix Cardiovascular, Inc | Prosthetic tissue valve |
| US8877224B2 (en) * | 2009-02-18 | 2014-11-04 | Cormatrix Cardiovascular, Inc | Compositions for preventing cardiac arrhythmia |
| US20160184480A1 (en) * | 2014-12-31 | 2016-06-30 | Daniel Cox | Crosslinkable 3d printed biomaterial-based implants and methods of manufacture thereof |
| US20160303804A1 (en) * | 2015-04-16 | 2016-10-20 | Siemens Aktiengesellschaft | Method and System for Advanced Transcatheter Aortic Valve Implantation Planning |
| CN106264791A (en) * | 2016-08-10 | 2017-01-04 | 青岛三帝生物科技有限公司 | Method and the medicine carrying aortic valve of medicine carrying aortic valve is prepared based on 3D printing |
| CN106362212A (en) * | 2016-10-21 | 2017-02-01 | 华中科技大学同济医学院附属协和医院 | Lipophilic decellularization solution, kit and method for removing tissue cells |
-
2017
- 2017-03-06 CN CN201710127726.5A patent/CN106726009A/en active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996032905A1 (en) * | 1995-04-19 | 1996-10-24 | St. Jude Medical, Inc. | Matrix substrate for a viable body tissue-derived prosthesis and method for making the same |
| CN1410036A (en) * | 2002-11-15 | 2003-04-16 | 谭强 | Tissue engineered valve |
| CN1775304A (en) * | 2005-11-30 | 2006-05-24 | 中国科学院上海硅酸盐研究所 | Preparation method of biologically active artificial biological valve |
| US8679176B2 (en) * | 2007-12-18 | 2014-03-25 | Cormatrix Cardiovascular, Inc | Prosthetic tissue valve |
| CN101385870A (en) * | 2008-11-03 | 2009-03-18 | 中国人民解放军第四军医大学 | A method for improving decellularized tissue engineering valve/vascular stent |
| US8877224B2 (en) * | 2009-02-18 | 2014-11-04 | Cormatrix Cardiovascular, Inc | Compositions for preventing cardiac arrhythmia |
| CN101548916A (en) * | 2009-05-08 | 2009-10-07 | 乐普（北京）医疗器械股份有限公司 | A medical equipment carrying extracellular matrix and its production method |
| CN103263381A (en) * | 2013-05-28 | 2013-08-28 | 武汉纺织大学 | Fiber type controllable drug sustained release system and preparation method thereof |
| US20160184480A1 (en) * | 2014-12-31 | 2016-06-30 | Daniel Cox | Crosslinkable 3d printed biomaterial-based implants and methods of manufacture thereof |
| US20160303804A1 (en) * | 2015-04-16 | 2016-10-20 | Siemens Aktiengesellschaft | Method and System for Advanced Transcatheter Aortic Valve Implantation Planning |
| CN106264791A (en) * | 2016-08-10 | 2017-01-04 | 青岛三帝生物科技有限公司 | Method and the medicine carrying aortic valve of medicine carrying aortic valve is prepared based on 3D printing |
| CN106362212A (en) * | 2016-10-21 | 2017-02-01 | 华中科技大学同济医学院附属协和医院 | Lipophilic decellularization solution, kit and method for removing tissue cells |
Non-Patent Citations (2)
| Title |
|---|
| 周建良: "PEG交联去细胞瓣多信号复合材料生物学性能研究", 《中国博士学位论文全文数据库》 * |
| 邓诚 等: "瓣制备组织工程心脏瓣膜支架", 《临床心血管病杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331227A (en) * | 2018-09-18 | 2019-02-15 | 武汉纺织大学 | A method for improving mechanical properties of heart valve |
| CN113198045A (en) * | 2021-04-29 | 2021-08-03 | 武汉纺织大学 | Fitting type biological valve and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2688562B1 (en) | Mesh enclosed tissue constructs | |
| US8454678B2 (en) | Prosthetic implants including ECM composite material | |
| CN101478934B (en) | Bioengineered intervertebral discs and methods of making | |
| US6454803B1 (en) | External nasal valve batten implant device and method | |
| JP2022017489A (en) | Dual component mandrel for electrospun stentless fabrication of multi-valve valve | |
| WO2002102237A2 (en) | Tissue engineered mitral valve chrodae and methods of making and using same | |
| JP2006021060A (en) | Surgical prostheses | |
| CA2333058C (en) | Corporal tissue penile reconstruction | |
| CN109157305A (en) | Combined artificial cornea and preparation method thereof | |
| Namdari et al. | Nanofibrous bioengineered heart valve—Application in paediatric medicine | |
| Tan et al. | Tailor-made natural and synthetic grafts for precise urethral reconstruction | |
| CN106726009A (en) | Sustainer intervenes valve manufacture method | |
| US9925296B2 (en) | Mesh enclosed tissue constructs | |
| Ciolino et al. | Biologic keratoprosthesis materials | |
| Pyatin et al. | Recent medical techniques for peripheral nerve repair: Clinico-physiological advantages of artificial nerve guidance conduits | |
| CN216495865U (en) | Artificial ocular prosthesis table | |
| EP3439707B1 (en) | Engineered tissues having structural components embedded therein, and methods of making and using | |
| CN209136988U (en) | Breastbone prosthetic appliance | |
| CN221534224U (en) | 3D prints compound absorbable osteogenesis's of truss skull prosthesis | |
| JP2007037764A (en) | Artificial valve | |
| CN102415922B (en) | A controllable vascularized artificial bone graft | |
| CN109985274A (en) | Tissue engineered transcatheter valve skirt with regeneration function and preparation method thereof | |
| JP2007037763A (en) | Stent with artificial valve | |
| US12102527B2 (en) | Biological low profile, balloon expandable prosthetic heart valve, particularly aortic, for transcatheter implantation and the method of its manufacturing | |
| Blum et al. | Heart valve tissue engineering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180813 Address after: 430070 202 building, No. 2, No. 2, B9 building, 818 hi-tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei. Applicant after: Wuhan Wei Ke Medical Technology Co., Ltd. Address before: 430014 23, 4 tower, 24 eye three road, Jiang'an District, Wuhan, Hubei. Applicant before: Dong Nianguo Applicant before: Shang Xiaoke |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
| RJ01 | Rejection of invention patent application after publication |